Core Viewpoint - Siemens plans to reduce its 35 billion euro ($41 billion) stake in Siemens Healthineers by distributing shares of the medical equipment maker to its shareholders [1] Group 1 - The total stake being cut by Siemens is valued at 35 billion euros, equivalent to approximately 41 billion dollars [1] - The method of reduction involves giving shares of Siemens Healthineers directly to Siemens' shareholders [1]

Core Insights - IceCure Medical Ltd. will release its financial and operational results for the nine months ended September 30, 2025, on November 19, 2025, before the Nasdaq Stock Market opens [1] - A conference call to discuss these results and other corporate developments is scheduled for the same day at 10:00 a.m. EST [2] Company Overview - IceCure Medical specializes in developing and marketing advanced liquid-nitrogen-based cryoablation therapy systems aimed at destroying both benign and cancerous tumors through freezing [2] - The company's primary focus areas include breast, kidney, bone, and lung cancer, with its flagship ProSense® system marketed globally [2] Upcoming Events - The conference call will be accessible via a live webcast, and a recording will be available afterward on the company's investor relations website [2]

Core Insights - Nuwellis, Inc. reported steady performance and key milestones in critical care, pediatrics, and hospital-based outpatient therapy, focusing on cardiorenal conditions [1][3] Financial Performance - Total revenue for Q3 2025 was $2.2 million, a decrease of 6% year-over-year but an increase of 29% sequentially from Q2 2025 [4][7] - On a pro-forma basis, revenue grew approximately 7% year-over-year after excluding one-time revenue from SeaStar Medical [4][7] - Gross margin was 65.2%, down from 70.0% in the prior year quarter, attributed to unfavorable manufacturing utilization [5] - Operating expenses totaled $4.1 million, up 30% year-over-year, reflecting investments in rebuilding the U.S. sales force and sustaining engineering [6] - The operating loss was $2.7 million, compared to $1.5 million in the previous year [6][19] Business Developments - The company launched a new 24-hour circuit and dual-lumen extended-length catheter, enhancing provider flexibility in therapy delivery [7] - The first Aquadex therapies were delivered in a hospital-based outpatient setting, marking a significant step in expanding access to ultrafiltration therapy [7] - Pediatric product development accelerated through an NIH-funded collaboration for the Vivian™ pediatric CRRT system [7] - Nuwellis initiated a manufacturing transition to KDI Precision Manufacturing and began winding down international operations to focus on U.S. market growth [7] Cash Position - The company ended the quarter with $3.1 million in cash and cash equivalents and remains debt-free [6][19]

Core Insights - BD (Becton, Dickinson and Company) has launched the PureWick Portable Collection System, a battery-powered personal urine management device aimed at improving mobility for wheelchair users [1][2][3] Product Overview - The PureWick Portable Collection System is designed to manage urinary incontinence discreetly and effectively, building on the success of the existing PureWick Urine Collection System, which is the leading external catheter in hospitals [2][5] - The device utilizes gentle suction technology to draw urine away from the body into a collection canister, facilitating easy disposal [2][5] Market Impact - Urinary incontinence affects approximately 25 million Americans, significantly impacting their confidence and quality of life, particularly for those with mobility challenges [3] - The introduction of this portable system aims to empower users to regain confidence and independence, allowing them to engage more fully in daily activities [3][6] User Trust and Adoption - Over 55 million PureWick External Catheters have been sold, with more than 4,500 hospitals and rehabilitation facilities in the U.S. utilizing this technology [5] - A survey indicated that over 90% of users and caregivers would recommend the PureWick Urine Collection System, highlighting its effectiveness and trustworthiness [5] Features and Benefits - The system is designed for comfort and discretion, operating quietly and being easy to set up for use at home or on the go [8] - It offers freedom of movement with a lightweight design and a battery life of up to eight hours, allowing it to be used beside a bed, chair, or mounted on a wheelchair [8] - The device helps reduce the risk of skin irritation by effectively drawing urine away from the body, thus maintaining user dignity and active lifestyle [8]

Siemens is finalizing options to reduce a majority stake in its former medical equipment unit after the €35 billion holding turned into a drag on its share price https://t.co/DvTtzGL6DO ...

Core Insights - Shoulder Innovations, Inc. reported a significant revenue growth of 58% in Q3 2025, reaching $11.8 million compared to $7.5 million in Q3 2024, driven by an increase in implant systems sold and new customer acquisitions [2][14] - The company anticipates a full-year revenue of $45 million to $46 million for 2025, representing a growth of approximately 42% to 45% over 2024, an increase from previous guidance of $42 million to $44 million [8] - The company is focused on expanding its market share in the $2.8 billion global shoulder surgical care market, leveraging its innovative product ecosystem and strong clinical results [2][12] Financial Performance - Net revenue for Q3 2025 was $11.8 million, a 58% increase from $7.5 million in Q3 2024 [2][18] - Gross margin for Q3 2025 was 76.2%, slightly down from 76.5% in Q3 2024 [3] - Selling, general, and administrative expenses rose 78% to $15.1 million in Q3 2025, primarily due to increased headcount and legal costs [3] - Research and development expenses increased by 40% to $1.5 million in Q3 2025, reflecting investment in new product development [4] - Operating loss for Q3 2025 was $7.6 million, compared to a loss of $3.9 million in Q3 2024, with a net loss of $8.7 million compared to $4.1 million in the prior year [5][6] Market Position and Strategy - The company is expanding its I-Series humeral stem product line, including the full commercial launch of the InSet™ 70 and receiving FDA 510(k) clearance for certain fracture indications [14] - Shoulder Innovations aims to address challenges in shoulder arthroplasty through its ecosystem of products, digital solutions, and a differentiated commercial model [2][12] - The company emphasizes the importance of the number of implant systems sold as a key business metric to drive demand and revenue [11]

Core Insights - Xtant Medical Holdings, Inc. reported a total revenue of $33.3 million for Q3 2025, reflecting a 19% increase year-over-year, primarily driven by licensing revenue [1][3][13] - The company achieved a gross margin of 66.1%, up from 58.4% in the same quarter of the previous year, attributed to a favorable sales mix and greater scale [3][13] - Xtant Medical reiterated its full-year 2025 revenue guidance of $131-$135 million, indicating an expected growth of 11%-15% over FY24 [1][8] Financial Performance - Operating expenses decreased to $19.5 million in Q3 2025 from $20.1 million in Q3 2024, mainly due to reduced compensation and commission expenses [4][13] - The company reported a net income of $1.3 million, or $0.01 per share, compared to a net loss of $5.0 million, or $(0.04) per share, in Q3 2024 [4][13] - Non-GAAP adjusted EBITDA for Q3 2025 was $4.5 million, a significant improvement from an adjusted EBITDA loss of $1.0 million in the same period last year [5][13] Cash Flow and Assets - As of September 30, 2025, Xtant Medical had cash and cash equivalents of $10.6 million, an increase from $6.2 million at the end of 2024 [7][13] - The company generated $4.6 million in cash from operations in Q3 2025, compared to cash used in operations of $1.7 million in Q3 2024 [13] Strategic Developments - The anticipated sale of certain non-core spinal implant assets and international businesses to Companion Spine is expected to close by the end of 2025, allowing the company to focus on its core biologics business [2][13] - Xtant Medical launched CollagenX™, a bovine collagen particulate product aimed at enhancing surgical wound closure and promoting healing [13][21]

Accessibility StatementSkip Navigation CANTON, Conn., Nov. 10, 2025 /PRNewswire/ --Â Kelyniam Global, Inc. (OTC: KLYG), a leader in custom cranial and craniofacial implants, today reported financial results for the third quarter ended September 30, 2025. Q3 2025 Financial Highlights (Compared to Q3 2024) "Sales have faced headwinds this year from a slow distributor ramp-up and temporary market share shifts, but through Q3, we're steadily catching up to 2024 levels and building a stronger foundation for sust ...

Company Overview - Crown Reserve Acquisition Corp. I is a blank check company formed to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities [2] - The company may pursue acquisition opportunities across various industries but will focus on sectors where it has core competencies, including pharma, medical technology, medical equipment, and healthcare IT [2] Initial Public Offering (IPO) Details - The company closed its initial public offering of 17,250,000 units at a price of $10.00 per unit, resulting in gross proceeds of $172,500,000 [1] - The units began trading on the Nasdaq Global Market under the ticker symbol "CRACU" on November 7, 2025 [1] - Each unit consists of one Class A ordinary share, one-half of one redeemable warrant, and one right to receive one-fifth of one Class A ordinary share upon the consummation of an initial business combination [1] - An amount equal to $10.00 per unit was deposited into a trust account upon the closing of the offering [1] Management Team - The management team is led by Prashant Patel, Chief Executive Officer and Chairman, and Eric Sherb, Chief Financial Officer and Director [3] - The Board includes members Michael Peterson, Donald G. Fell, Avinash Wadhwani, and Mayur Doshi [3] Advisory and Management Support - Polaris Advisory Partners, a division of Kingswood Capital Partners LLC, acted as the sole book-running manager for the offering [4] - Thunder Rock Capital, LLC, a division of Finalis Securities LLC, served as an advisor to the company's management team [4] Regulatory Information - A registration statement relating to the securities was filed with the U.S. Securities and Exchange Commission (SEC) and became effective on September 26, 2025 [5]

Core Viewpoint - Siemens is expected to announce its strategy for reducing its stake in Siemens Healthineers, valued at 35 billion euros ($41 billion) [1] Company Summary - Siemens Healthineers is a significant asset for Siemens, and the planned reduction in stake indicates a strategic shift within the company [1] - The announcement is anticipated to provide insights into Siemens' broader financial strategy and capital allocation [1] Industry Summary - The engineering sector, particularly in healthcare technology, is witnessing shifts as companies reassess their investment strategies [1] - Stake adjustments in major firms like Siemens may influence market dynamics and investor sentiment within the healthcare technology industry [1]